News & Events
Integrated "omics" study of clear cell renal cell carcinoma.
FOXA1 is a principal oncogene in AR-dependent prostate cancer; FOXA1 alterations can be stratified into three main structural classes.
New compounds show promise for the treatment of metastatic castration-resistant prostate cancer.
Building a compendium of circRNA in cancer that could serve as a valuable resource for the development of circRNAs as diagnostic or therapeutic targets across cancer types.
Read about the Michigan Legacy Tissue Program by MCTP faculty member, Rohit Mehra.
A new grant to Dr. Arul Chinnaiyan will provide long-term support to explore precision oncology
Researchers identify a new subtype of prostate cancer defined by loss of CDK12 gene.
Researchers at MCTP identified a novel long noncoding RNA, ARLNC1 that is strongly associated with AR signaling in prostate cancer progression.
THOR is an ultraconserved lncRNA that exhibits expression exclusively in testis and a broad range of human cancers.
New clinical fluorescence in situ hybridization (FISH) assays to detect TFE3 and TFEB translocations offered through UM genitourinary FISH service (at MLabs).
In one of the largest and most comprehensive efforts to examine the genetic and molecular landscape of advanced cancer, researchers at the University of Michigan Comprehensive Cancer Center sequenced the DNA and RNA of 500 patients with metastatic cancer.
A review of MI-ONCOSEQ clinical sequencing program at Michigan Medicine
Immunohistochemical evaluation of markers suggest a role for prospective FH IHC to screen cutaneous leiomyoma patients for HLRCC.
New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers.
Dr. Chinnaiyan's research career featured in an article in the journal, Cancer
Several MCTP members were recent award recipients
MCTP wins Occupational Safety & Environmental Health Safety First Recognition Award.
MCTP members were recipients of several awards.
Discovery of a functional KRAS-AGO2 interaction may have implications for novel therapeutic strategy for KRAS-driven cancers.
AACR leadership and members including Dr. Arul Chinnaiyan meet with FDA officials and Vice President's senior staff.
MCTP researchers and collaborators have published the results from the first 102 pediatric patients enrolled in the PEDS-ONCOSEQ clinical sequencing study.
New study is the first comprehensive molecular landscape of metastatic castrate-resistant prostate cancer.
MLL-menin inhibitor disrupts AR-MLL complex interaction that results in blocking AR signaling and inhibiting the growth of castration-resistant tumors.
MCTP researchers, Nalla Palanisamy and Rohit Mehra, were featured in Advanced Cell Diagnostics' "Researcher in the Spotlight" newsletter where they discussed their work.
< newest 1 2 oldest >
MCTP researchers analyzed the global landscape of a portion of the genome that has not been previously well-explored – long non-coding RNAs (lncRNAs).